PEAK6 Investments’s Arbutus Biopharma ABUS Stock Holding History

PEAK6 Investments’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-62,400	Closed	-$149K	–	4327
2022 Q3	$119K	Buy	+62,400	New	+$147K	﹤0.01%	3987

Other funds holding ABUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PEAK6 Investments's ABUS Position: Q4 2022 in Review

PEAK6 Investments sold out of Arbutus Biopharma (ABUS) in Q4 2022, closing a stake of 62,400 shares — an estimated $149K sold.

PEAK6 Investments first reported a position in ABUS in Q3 2022 and held it in 1 quarter. The position peaked at $119K in Q3 2022. 114 funds tracked by Wall St. Rank hold ABUS as of Q4 2022.

PEAK6 Investments reported no remaining Arbutus Biopharma position as of Q4 2022 after selling out during the quarter.
PEAK6 Investments sold 62,400 Arbutus Biopharma shares in Q4 2022, an estimated $149K.
PEAK6 Investments first reported a position in Arbutus Biopharma in Q3 2022 and held it in 1 quarter.
PEAK6 Investments's Arbutus Biopharma position peaked at $119K in Q3 2022.
114 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2022.

Based on PEAK6 Investments's 13F filing for Q4 2022, filed 10 Feb 2023.